Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 11 points (-0.1%) at 15,227 as of Tuesday, June 11, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 560 issues advancing vs. 2,425 declining with 97 unchanged. The Drugs industry currently sits up 0.1% versus the S&P 500, which is down 0.37. On the negative front, top decliners within the industry include Merck ( MRK), down 1.10, and Novartis ( NVS), down 0.47. Top gainers within the industry include Alexion Pharmaceuticals ( ALXN), up 3.8%, Celgene Corporation ( CELG), up 1.5% and Amgen ( AMGN), up 0.5%. TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today: 5. Forest Laboratories ( FRX) is one of the companies pushing the Drugs industry lower today. As of noon trading, Forest Laboratories is down $0.90 (-2.2%) to $40.13 on heavy volume Thus far, 1.4 million shares of Forest Laboratories exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $39.78-$40.51 after having opened the day at $40.51 as compared to the previous trading day's close of $41.03. Forest Laboratories, Inc. develops, manufactures, and sells branded forms of ethical drug products primarily in the United States and Europe. Forest Laboratories has a market cap of $10.8 billion and is part of the health care sector. Shares are up 14.5% year to date as of the close of trading on Monday. Currently there are 6 analysts that rate Forest Laboratories a buy, 2 analysts rate it a sell, and 8 rate it a hold. TheStreet Ratings rates Forest Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Forest Laboratories Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.